Karyopharm Therapeutics Inc (KPTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has a cash flow conversion efficiency ratio of 0.076x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.93 Million) by net assets ($-330.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KPTI market cap for the company's overall valuation and market capitalisation.
Karyopharm Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Karyopharm Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Karyopharm Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Karyopharm Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Karyopharm Therapeutics Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bo Lak
KO:002760
|
-0.013x |
|
Namyang Dairy Products Co Ltd Peffered Series 1
KO:003925
|
0.003x |
|
Inhwa Precision Co. Ltd
KQ:101930
|
0.012x |
|
Strategic Investments A/S
CO:STRINV
|
0.097x |
|
Estoril Sol SGPS SA
LS:ESON
|
0.102x |
|
Indah Prakasa Sentosa PT Tbk
JK:INPS
|
-0.124x |
|
BIT Computer Co. Ltd
KQ:032850
|
0.031x |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
0.085x |
Annual Cash Flow Conversion Efficiency for Karyopharm Therapeutics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Karyopharm Therapeutics Inc from 2011 to 2025. View KPTI live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-292.93 Million | $-75.37 Million | 0.257x | -62.46% |
| 2024-12-31 | $-186.02 Million | $-127.49 Million | 0.685x | +0.67% |
| 2023-12-31 | $-136.21 Million | $-92.72 Million | 0.681x | -92.42% |
| 2022-12-31 | $-16.66 Million | $-149.55 Million | 8.979x | +567.86% |
| 2021-12-31 | $-79.67 Million | $-107.12 Million | 1.344x | +142.41% |
| 2020-12-31 | $50.55 Million | $-160.23 Million | -3.170x | +17.31% |
| 2019-12-31 | $49.77 Million | $-190.82 Million | -3.834x | -341.33% |
| 2018-12-31 | $183.17 Million | $-159.12 Million | -0.869x | -52.56% |
| 2017-12-31 | $129.46 Million | $-73.72 Million | -0.569x | -9.47% |
| 2016-12-31 | $162.24 Million | $-84.39 Million | -0.520x | -9.73% |
| 2015-12-31 | $198.37 Million | $-94.03 Million | -0.474x | -90.53% |
| 2014-12-31 | $206.79 Million | $-51.45 Million | -0.249x | -27.25% |
| 2013-12-31 | $154.93 Million | $-30.29 Million | -0.196x | -135.14% |
| 2012-12-31 | $-27.88 Million | $-15.51 Million | 0.556x | -17.67% |
| 2011-12-31 | $-12.65 Million | $-8.55 Million | 0.676x | -- |
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more